GRM1 and melanoma: Also, the understanding that glutamate the ligand for mGlu1 contributes to aberrant melanocyte growth in cells harboring the receptor through an autocrine loop has led to the utility of a glutamate release inhibitor, Riluzole as a potential anti-melanoma drug.